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Abstract
Objective: Buprenorphine, a medication for opioid use disorder, remains vastly underutilized despite its proven
efficacy. This study sought to evaluate which strategies, within a system that employed a variety of concurrent
strategies, effectively increased access to buprenorphine.
Methods: Over the course of 15 months, 25 federally qualified health centers were invited to participate in four
commonly used implementation strategies. This study examines the impact of clinic attendance at strategy events on
change in numbers of patients prescribed buprenorphine and numbers of buprenorphine-waivered providers by clinic.
Results: There was a nearly three-fold increase (2.84) in patients on buprenorphine and two-fold increase (1.90) in
number of buprenorphine-waivered prescribers during the project period. Clinics attending at least half of the available
didactic webinars and Project ECHO sessions were significantly more likely to increase both patients and providers,
respectively, than clinics attending fewer events.
Conclusions: In order to make informed decisions about how best to increase access to medications for opioid
use disorder, systems and organizations need data on which implementation strategy options are most effective.

Keywords: Medications for opioid use treatment (MOUD);
Medications for addiction treatment (MAT); Opioid use disorders;
Implementation strategies; Project ECHO; Expert coaching; Workforce
training

rates of OUD in the Medicaid populations they serve [13]. As such,
forty-eight percent of FQHCs provide at least one of the three MOUD
medications, significantly higher than the national average among
non-FQHC primary care practices [16].

Introduction

Despite these advances, there is little research on successful MOUD
expansion efforts in primary care settings beyond specialty substance
use treatment programs [17-26]. Many organizations employ multiple
implementation strategies to address the above barriers, with the hopes
that all or some may improve adoption of MOUD practice [7,27-31]. The
cumulative effect of multiple strategies makes it difficult to determine
which strategy(ies) directly improved outcomes. An accumulation of
implementation science research supports tailoring chosen strategies
to specified barriers; for greater precision and to accurately evaluate
effects [30-35]. Without deconstructing which strategies effectively
expand MOUD access, organizations may miss the mark on which
reforms to focus on to address the opioid epidemic.

Opioid related overdose mortality rates continue to rise [1]. The
most effective treatments for opioid use disorders (OUD) include
three FDA-approved medications: buprenorphine, methadone, and
naltrexone [2,3]. However, access to medications for OUD (MOUD)
remains limited due to inadequate numbers of buprenorphinewaivered providers to meet treatment need and limited prescribing
to patients who could benefit from MOUD [4,5,6]. Through the 21st
Century Cures Act, over $7.5 billion has been distributed to U.S. states
and territories. These states have deployed a variety of implementation
strategies with this funding to increase MOUD adoption and patient
access. However, it has yet to be discovered which, if any, of these
strategies are most effective.
Despite initiatives through federal, state, and philanthropic
funding to increase both the providers authorized to and patients
prescribed MOUD [7], barriers to expansion persist. Stigma toward
OUD patients, low provider confidence in delivering specialty care,
lack of institutional support, and reimbursement concerns continue
to hinder primary care physicians from obtaining waivers [8,9]. Of
those that have adopted MOUD, many do not treat to their provider
caps; 30 patients in their first year, 100 patients in their second, and 275
patients subsequently [4,5,10]. Patients also themselves face barriers
to treatment; perceived associations with “addiction,” beliefs around
medicated treatment, and high out-of-pocket costs [11,12].
Federally Qualified Health Centers (FQHCs) have been identified
for their potential to reach patients with OUD who do not seek
services in specialty addiction programs [7,13-15]. This is due to both
a strong existing primary care infrastructure and higher than average
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In this report, we examine the impact of four strategies: in-person
workshops, Project ECHO, expert coaching, and didactic webinars
on reach and adoption of MOUD among 25 FQHC clinics across the
state of California. All clinics were eligible for and offered all strategies.
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Clinics participated in an array of strategies as they elected to do
so. There was no randomization or matching in the design. This is
common of many expansion projects; offering an array of strategies
with the intent that some of them will prove effective. However, this
study seeks to tease out which strategies were most effective on target
outcomes, saving time and money for future endeavors.
As a function of participation in the strategies offered, we examine
the change in: 1) the number of patients prescribed buprenorphine
(reach); and 2) the number of waivered providers (adoption).

Methods
Participant Organizations and Sampling
In early 2016, the Health Resources and Service Administration
distributed grants to 36 California FQHCs to improve MOUD access.
Twenty-five clinics chose to participate in additional grant-sponsored
technical assistance programming over 15 months from September
2016 to February 2017. Clinics that participated in implementation
strategies provided by this additional grant, comprise the final
analytical sample (Figure 1).
Implementation Strategies: Four implementation strategies
were made available to each of the participating clinics: 1) in-person
workshops; 2) Project ECHO; 3) expert coaching; and 4) didactic
webinars. The strategies included both in-person and remote learning
options.
In-Person Workshops: Four full-day (6-hour) workshops were
provided and held throughout California starting in October 2016 and
continuing through December 2017. The content of the workshops
included clinical aspects of medication prescribing and managing
complex conditions, as well as process improvement tactics to support
practice change in protocols and workflow. In-person workshops have
shown moderate success in increasing adoption of evidence-based
mental health care and reducing practice variation [36-39]. However,
impact on MOUD prescribing has yet to be tested.
Project ECHO: Project ECHO uses teleconferenced didactic
presentations and case-based discussions to expand specialty care
in primary care settings [22]. A total of 16 hour-long sessions were
held monthly from November 2016 to January 2017 and focused on

topics relevant for healthcare providers. Research has shown Project
ECHO can effectively train generalist physicians in pain management,
treatment of substance use disorders, and reduce opioid overprescribing [17-19,21,22]. This study is among the first to specifically
investigate MOUD prescribing [29].
Expert Coaching: Participating clinics were assigned to one of
five expert coaches available for monthly, regularly scheduled phone
consultations for MOUD expansion needs. While dosage varied, each
clinic that opted into the strategy met at least once a month with their
paired coach. They provided support on topics such as the mechanics
of induction, overcoming the prescribing fear of prescribing, workflow,
team-based care, and managing complex cases. Coaching models have
shown success in integrating mental health care in primary care settings
and reducing practice variation [23-26]. Several studies are currently
underway to evaluate expert coaching effects on buprenorphine
prescribing, but specific to emergency department settings [40,41].
Didactic Webinars: The monthly didactic webinars included
interactive, real- time training tools on how to address MOUD in
community-based settings. They occurred between the months of
August 2016 and October 2017 for a total of 15 one- hour webinars.
Topics included the hub and spoke treatment model, patient
confidentiality, naloxone prescribing, and treating alcohol use disorder.

Data Collection
Baseline and endpoint data on the primary and secondary outcomes
were in clinic reports in September 2016 and December 2017. Data on
the primary implementation outcomes, which included the number
of patients on addiction medications (reach) and number of waivered
providers (adoption), were collected via these reports. Because data
were aggregated at the clinic-level, the study was deemed exempt and
approved by Stanford University’s institutional review boards.

Variables
Implementation Strategy Attendance: Attendance – a proxy
for participation – is the primary independent variable. Clinics were
marked as attending if one staff member signed-in for in-person
events or logged-in for virtual events, which was tracked through
Salesforce roll-up software. We measured attendance dichotomously;
if a clinic attended more or less than half of the offered sessions for a

Figure 1: CONSORT diagram- Clinic Enrollment and Participation.
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given strategy type. However, this differed for expert coaching, which
was categorized as binary since clinics either engaged with or did not
engage with a coach. For in-person learning sessions, attendance across
all possible sessions was high (84%), so this variable was categorized as
attending all (4) or less than all the events.

addiction counseling for OUD and 2 waivered-providers. The clinics
were predominantly urban (84%) and approximately equitably
distributed between northern (12 clinics) and southern (13 clinics)
California. The clinics employed a large number of employees (Mdn =
413) across many clinic sites (Mdn = 6).

Reach: Patients Prescribed Buprenorphine: A primary dependent
variable for this study was reach, or the number of patients prescribed
buprenorphine [42]. Clinic-level data was obtained from baseline and
endpoint survey collection in September of 2016 and December 2017,
respectively. Reach was operationalized as the change in number of
patients between these time points.

The CONSORT diagram in Figure 1 delineates program enrollment
and attendance. Of the 36 California grantees, 25 participated in the
final study. Overall, implementation activities were well attended, but
attendance varied by implementation strategy (Figure 1). All clinics
attended at least one in-person workshop (100%), with an overall
attendance of 84% across four events. Project ECHO attendance was
lower with 13 clinics attending at least one session (52.0%) and an
overall attendance of 35.7% across all 16 events. Seventeen of the
clinics utilized expert coaching (68.0%). All clinics attended at least
one of the 15 didactic webinars (100%), with 54.8% attendance
across all sessions. Across all available strategy types (in-person
workshops, Project ECHO, expert coaching, and didactic webinars),
seven clinics (28.0%) attended only two of the strategies, seven
clinics (28.0%) attended three, and 11 clinics (44.0%) participated
in all four activities.

Adoption: Number of Waivered Providers
The second outcome of interest was adoption or change in number
of waivered providers over the study period. This was a continuous
variable calculated as the difference in number of waivered providers
from endpoint to baseline.

Data Analysis
This study is a naturalistic, non-randomized, retrospective analysis
of baseline and endpoint aggregated data from 25 FQHCs in the
state of California. Mann-Whitney unpaired tests (U-tests) tested for
significant differences in outcomes between attendance groups by
strategy. All tests were completed using R version 3.6.1.

Results
Table 1 illustrates clinic-level characteristics of enrolled clinics.
Clinics had a median of 28 baseline patients receiving MOUD or
Clinic Characteristic and Attendance Group

MOUD Implementation Outcomes
Reach: Patients Prescribed Buprenorphine
Change in patients prescribed buprenorphine from baseline
to endpoint are depicted in Figure 2a, by activity type. Reports
demonstrated an increase in reach over time, from 626 patients to
1,776 patients prescribed buprenorphine over the study period, a
nearly three-fold increase (2.84).
Total (N=25)
n/mediana

(%/range)

Patients prescribed buprenorphine

25

(-6, 110)

Waivered-providers

2

(0, 13)

Clinic-level change in

Clinic Characteristics
Number of patients at Baseline

2

(0, 88)

Baseline waivered-providers

2

(0, 28)

Baseline eligible providers

18.5

(7, 70)

Baseline MATᵇ participants

28

(0, 527)

Clinic sites

6

(1, 24)

Employees

413

(25, 3000)

Rural

4

16%

Urban

21

84%

All sessions (4)

12

50%

Fewer sessions (<4)

13

50%

>= 9 sessions

9

64%

< 9 sessions

16

36%

Engaged

17

68%

Not Engaged

8

32%

>= 9 sessions

13

52%

< 9 sessions

12

48%

Urbanicity

Clinic Attendance In-person workshops

Project ECHO

External Facilitation

Didactic webinars

a

Median and range apply to the continuous variables, n and % apply to categorical variables. bMedication for Addiction Treatment (MAT): Baseline variable collected
patients on MOUD medications OR receiving addiction counseling. These are two separate clinical treatments, but baseline reporting did not differentiate.
Table 1: Clinic Characteristics and Implementation Strategy Attendance
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Adoption: Number of Waivered Providers
Change in the number of waivered providers from baseline to
endpoint are depicted in Figure 2b. The overall number of providers
saw a nearly two-fold increase (1.90), from 126 to 201 waivered
providers over the study period.

Implementation Strategy Attendance and MOUD Outcomes
The group difference results between different attendance subgroups are presented in Table 2. The results indicated that the median

change in number of patients prescribed buprenorphine was greater
for clinics that attended half or more of the available didactic webinars
(Mdn = 32.0) than for clinics that did not (Mdn = 14.0), W = 34.0,
p=0.02. The change in buprenorphine-waivered providers was also
higher for clinics that attended half or more of the available Project
ECHO sessions (Mdn = 5.0) compared to clinics that attended fewer
sessions (Mdn = 1.0), W = 24.0, p=0.02. There were no betweengroup differences in either outcome for in-person sessions or expert
coaching. These results are also depicted in Figure 2a and 2b which
represent change in clinic outcomes by strategy type. It should be noted

Figure 2: Change in Study Outcomes by Clinic Attendance and Strategy Type
2a. Change in Patients Prescribed Buprenorphine by Strategy Type and Attendance
2b. Change in Waivered-Providers by Strategy Type and Attendance

Clinic Attendance

N

Median change in outcome (from baseline to endpoint)
Patients prescribed buprenorphine

Waivered- providers

In-person workshops
All sessions(4)

12

28.0

2.0

Fewer sessions (<4)

13

22.5

3.0

>= 9 sessions

9

26.0

5.0*

< 9 sessions

16

21.5

1.0*

Project ECHO

External Facilitation
Engaged

17

23.0

2.0

Not Engaged

8

27.0

3.5

>= 9 sessions

13

32.0*

3.5

< 9 sessions

12

14.0*

1.0

Didactic Webinars

Note. Difference between groups using Mann-Whitney U-test; *significant at p < 0.05
Table 2: Clinic Attendance by Median Study Outcome.
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that clinic attendance of these results did not control for dual clinic
participation in more than one strategy type.

Discussion
Summary of Findings
Overall, there was a three-fold increase in patients accessing
MOUD and a two- fold increase in providers adopting MOUD. We also
explored the impact of attendance at four implementation strategies on
increased access to MOUD and waivered providers among 25 FQHC
clinics. Clinics that attended more than half of the available didactic
webinars experienced significantly greater increases in patients
prescribed buprenorphine than clinics that attended less than half.
Clinics that attended more than half of the offered Project ECHO
sessions also experienced significantly higher growth in waiveredproviders compared to clinics with lower attendance. These results
may be due to the nature of both strategies. Didactic webinars were
available to all members of a clinic and target overall best-practices for
addressing MOUD. Project ECHO as a model is specifically targeted
to generalized providers, with the intent to expand their knowledge of
specialty – in this case, addiction – service. This may explain the impact
of this strategy on the outcome of interest.
These results provide mixed alignment with current research on
MOUD expansion efforts. Clinic attendance at Project ECHO sessions
did significantly increase odds of waivered-provider growth, in
alignment with recent Project ECHO research on increased specialtypractice adoption in primary care settings [21,43]. Didactic webinars
were successful in increasing patients prescribed buprenoprhine,
though other studies have found them to be less effective [13]. The
in-person workshops and expert coaching strategies did not have
significant effects on growth in the current study. This diverges from
recent literature demonstrating increased MOUD provider efficacy
and other evidence-based practice adoption for in-person workshops
and coaching, respectively [13,24,25,39].

Limitations
As a naturalistic and non-randomized study, the lack of a
comparator limits causal interpretations of implementation strategies
and their impact on MOUD reach and adoption. For example,
clinics already motivated to expand MOUD may have attended more
implementation strategy sessions rather than these strategies causing
MOUD expansion. Data on reach and adoption were reported by the
clinics in a standardized approach, but were not objectively verified by
administrative, health record, or claims data. Although participation in
the strategies was carefully tracked for any clinic member attendance,
neither how many staff nor staff member role (e.g., physician, behavioral
health clinician, clinic manager) were examined. This is a significant
limitation because the constellation of implementation strategies was
offered to the FQHCs as a team-based approach to MOUD care. Teambased approaches to MOUD that involve the prescriber, a nurse or
care manager and a behavioral health clinician are well-documented
[44]. The present study did not evaluate the degree to which all clinic
members participated in the strategies. Combination and sequencing
of the strategies may also have produced synergistic or interactive
effects. A few didactic webinar sessions early in the project may have
been sufficient to learn the mechanics of prescribing MOUD. But as
more complex patients presented, and more complicated clinical
decisions were being made, the importance of case-based learning
(Project ECHO) and developing care pathways (expert coaching) may
have been increasingly valuable. The expert coaching program was also
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based on models of facilitation, but with deviations [23,24]. A more
direct implementation of this model may have produced increased
effects. Lastly, because this was a sample of FQHCs only, the findings
may not be generalizable to other types of primary care practices.
Further research should expand this investigation to other primary
care settings and with more robust, randomized-control design.

Implications and Future Research
Our study is among the first to examine the influence of commonly
used implementation strategies in a MOUD reach and expansion
endeavor. In a 15-month period, significant increases in MOUD reach
(more patients) and MOUD adoption (more prescribers) were major
and positive outcomes. There is no benchmark for expected increases
in reach or adoption at present. The increases reported here can be
framed as positive implementation outcomes. The unclear association
between specific implementation strategies (i.e. the interventions of
implementation) and implementation outcomes is also important. This
points to a need for more rigorously designed, controlled studies on
strategies for MOUD expansion. Endeavors to scale up evidence-based
addiction treatments such as MOUD could benefit from the selection
and matching of strategies to specific contextual barriers and needs
rather than a la carte approaches [31-34]. Systems and organizational
decision-makers often express a desire for tailored and efficiency in
approaches, but lack the validated research to guide choices about
which strategies to use [27,32,33]. National, state, regional, and local
endeavors may address the opioid epidemic with greater efficiency
by adapting implementation strategies to public health outcomes. In
adding specificity in their strategy selection, they may move the needle
on reduced overdose mortality and the benefits of effective treatments.
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